Craig Lindsley

Days’ work to identify highly potent and selective 5-HT2B antagonists was recognized by the Rosalind Franklin Society Read More

The Warren Center for Neuroscience Drug Discovery opened its doors to the Nashville community to share firsthand the pioneering work it is conducting on Alzheimer’s disease, Parkinson’s disease, addiction, and more. Read More

Using computer-aided drug design, the labs of Heidi Hamm, Jens Meiler, and Craig Lindsley generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read More

Phase I clinical trial of a drug was successfully completed at the Warren Center for Neuroscience Drug Discovery, with promise to treat Alzheimer’s and other neurodegenerative diseases. The compound, named VU319, is the first Vanderbilt end-to-end drug discovery effort related to memory loss, starting from the earliest basic science research through human clinical trials. Read More

Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read More

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read More

Research by David Merryman and Craig Lindsley has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects. The article, “Development of a Peripherally Restricted… Read More

Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and… Read More

Craig Lindsley, the William K. Warren, Jr. Professor of Medicine and director of Vanderbilt University’s  Warren Center for Neuroscience Drug Discovery, and Jeffrey Conn, founding director of the WCNDD and professor emeritus of pharmacology, have contributed seminal work… Read More

Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Down syndrome is a condition in which a person’s having… Read More